Clinical experience with the use of citicoline in mild cognitive impairment of vascular origin
Open Access
- 15 August 2023
- journal article
- research article
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (4) , 74-79
Abstract
Cardiovascular factors significantly increase the risk of vascular cognitive impairment (VCI). Currently, there are no specific treatments for VCI. A promising therapeutic strategy is the administration of citicoline, which has a neuroprotective effect.Objective: to evaluate the effect of treatment with citicoline (Noocil®) on cognitive function and quality of life (QoL)in patients with mild cognitive impairment (MCI) developed in a background of arterial hypertension and cerebral arteriosclerosis.Material and methods. An open-label prospective observational study enrolled 32 patients with neuroimaging-confirmed vascular cognitive impairment who received baseline therapy (antihypertensive, lipid-lowering, and antiplatelet therapy) and achieved target blood pressure and low-density lipoprotein cholesterol levels. All patients were assessed with a neuropsychological status assessment (MoCA-test). The efficacy of therapy was assessed by the Short Form-36 Quality of Life Questionnaire (SF-36).Results. The most common complaints of the patients were poor concentration, fatigue, forgetfulness, mood lability, sleep disturbances, more often in the form of early waking, and headaches. After 3 months of taking the drug Noocil®, all patients noted an increase in the ability to work, an improvement in concentration, memory and reproduction of the information received, both physical and mental indicators of QoL improved. The positive dynamics in terms of cognitive status (especially the functions of attention, short-term memory, several aspects of executive functions), QoL of patients, which was associated with the effect of Noocil® therapy, was accompanied by the absence of adverse events. A distinctive feature of domestic citicoline (Noocil®) is the presence of an original dosage form – a 240 ml bottle for oral administration, which improves adherence to long-term therapy.Conclusion. The efficacy, safety and good tolerability of Noocil® therapy in patients with predemental VCI was demonstrated.Keywords
This publication has 24 references indexed in Scilit:
- Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE studyClinical Interventions in Aging, 2013
- Vascular Contributions to Cognitive Impairment and DementiaStroke, 2011
- A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular diseaseActa Neurologica Scandinavica, 2010
- Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled studyThe Lancet Neurology, 2008
- Classification of vascular dementia in the Cardiovascular Health Study Cognition StudyNeurology, 2005
- Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderlyCochrane Database of Systematic Reviews, 2005
- The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive ImpairmentJournal of the American Geriatrics Society, 2005
- Midlife cardiovascular risk factors and risk of dementia in late lifeNeurology, 2005
- A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)International Clinical Psychopharmacology, 2002
- Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular DementiaStroke, 2002